MLYS - CIK 0001933414
The table below shows Mineralys Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $112.78M | $217.60M | $101.79M | $165.01M | $97.27M | $67.86M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $652.47M |
| $599.80M |
| $335.27M |
| $354.51M |
| $267.73M |
| $318.00M |
| Property, plant & equipment | $32.00K | $7.00K | $22.00K | $38.00K | $69.00K | $42.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $652.86M | $599.95M | $335.72M | $354.94M | $268.25M | $318.49M |
| Accounts payable | $1.12M | $1.12M | $3.16M | $373.00K | $3.11M | $1.71M |
| Total current liabilities | $14.72M | $23.52M | $22.17M | $13.39M | $31.32M | $28.40M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | -$496.51M | -$424.94M | -$388.00M | -$344.73M | -$253.57M | -$197.23M |
| Total equity | $638.14M | $576.43M | $313.55M | $341.56M | $236.93M | $290.10M |